Onyx expands laboratory facilities after record financial year
Onyx Scientific is set to increase the size of its UK-based site by investing in an additional site adjacent to its existing facility in North-East England
The expansion comes after the best performance in the company’s 15 year history and the additional space will primarily be used to increase its laboratory facilities, GMP suites and allocate space for storage of GMP materials, according to Onyx.
As part of the expansion initiative, Onyx Scientific said it has recruited several more chemists to support clients’ pre-clinical, development and early stage API manufacturing projects.
Denise Bowser, commercial director at Onyx Scientific, said: “Although we have come to the end of a very positive year, we have never been a firm to rest on our laurels. With the support of our parent company Ipca Laboratories, we are very much investing in our physical capacity, equipment and technical resource.
“We remain committed to supporting drug developers across the globe with routine chemistry and overcoming early stage complex chemistry challenges to allow them to progress, scale-up and meet clinical deadline with robust lead candidates.”
Denise added: “The decision to expand into an additional building has been driven by increased demand for GMP services as well as continuous flow projects and solid state chemistry, which has fully utilised our resources over the past 12 months.”
Alongside its work with large pharma, Onyx Scientific said it partners many specialty drug development firms and biotech organisations, supporting them with rapid progress from lead optimisation through Phase I-II.
The expansion comes after the best performance in the company’s 15 year history and the additional space will primarily be used to increase its laboratory facilities, GMP suites and allocate space for storage of GMP materials, according to Onyx.
As part of the expansion initiative, Onyx Scientific said it has recruited several more chemists to support clients’ pre-clinical, development and early stage API manufacturing projects.
Denise Bowser, commercial director at Onyx Scientific, said: “Although we have come to the end of a very positive year, we have never been a firm to rest on our laurels. With the support of our parent company Ipca Laboratories, we are very much investing in our physical capacity, equipment and technical resource.
“We remain committed to supporting drug developers across the globe with routine chemistry and overcoming early stage complex chemistry challenges to allow them to progress, scale-up and meet clinical deadline with robust lead candidates.”
Denise added: “The decision to expand into an additional building has been driven by increased demand for GMP services as well as continuous flow projects and solid state chemistry, which has fully utilised our resources over the past 12 months.”
Alongside its work with large pharma, Onyx Scientific said it partners many specialty drug development firms and biotech organisations, supporting them with rapid progress from lead optimisation through Phase I-II.